2018: Leo Pharma Foundation Grand
2018: ZonMw-Off Road grant
2018: RIMLS PhD grant
2017: National Institute of Health (NIH) - R35 subcontractor grant
2016: ZonMw grant 'Meer Kennis met Minder Proefdieren' - Module Maatschappelijke partners
2015: Willy van Heumen prize (development of alternatives for animal testing)
2015: ZonMw-NWO Veni laureate
2014: RIMLS Award for Best PhD thesis
2014: Cum Laude dissertation
2014: Frye Stipend for talented women in science, Radboud University Nijmegen
2013: Ter Meulen Fund, Short term fellowship KNAW
2013: ESDR Academy for Future Leaders in Dermatology, Florence Italy
2013: Best Poster prize, International Research Universities Network (IRUN) Immune Integrity Workshop
2013: Travel grant International Investigative Dermatology
2013: Travel grant Dutch Society for Dermatology and Venereology
2013: Best oral presentation, Nijmegen Institute for Infection Inflammation and Immunity Science Day
2012: Best oral presentation, Dutch Society for Experimental Dermatology (NVED)
2011/2012: Travel grant European Society for Dermatological Research
2011: Travel grant Dutch Skin Foundation
Ellen van den Bogaard studied biomedical sciences at the Radboud University (Nijmegen) and obtained her PhD in 2014 at the Dermatology department of the Radboudumc. She received a Cum Laude distinction for her dissertation: From skin development to disease pathogenesis: the power of 3D skin models. As of 2017 she is appointed junior principal investigator / assistant professor at the Radboudumc and she heads the Laboratory for Experimental Dermatology at Department of Dermatology.
My group studies skin biology and pathophysiology of inflammatory skin diseases. Our aim is to translate findings in basic science to applications in diagnostics and treatment of human disease. We therefore consider our research lines to have a true translational character. Over the years we have developed multiple 3D tissue engineered (organotpyic) skin disease models to study the interaction between epidermal keratinocytes, immune cells and the skin microbiome. The combination of these state-of-the-art culture models with advanced (next generation sequencing-based) methods enables us to elucidate disease mechanisms, identify novel targets for drug development and the screening of potentially new dermatological therapies.
Our main aim is to achieve a greater understanding of the molecular mechanisms of disease. By integrating fundamental and clinical research, we obtain multifaceted knowledge of (patho)physiological processes.